This study is the first, to our knowledge, to demonstrate that the ratio of GATA1 to GATA1s is reduced in certain subsets of patients with MDS, and these patients respond positively to treatment with luspatercept. The gene discussed is GATA1; the disease is myelodysplastic syndrome.